Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of rhBMP-2/CPM injection for low bone mineral density in postmenopausal women
NL-OMON35312Phase 2Active, not recruiting
- Sponsor
- Wyeth
- Start
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dibotermin alfa in osteoporosis and low bone mineral density (3 arms), sponsored by Wyeth. Primary endpoint: Change in proximal femur total hip bone mineral density. Started Feb 2010; status: active, not recruiting.
02
Drugs
dibotermin alfa
03
Conditions
osteoporosislow bone mineral density
Beyond the preview
Go deeper on NL-OMON35312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35312.